Establishing bioequivalence for inhaled drugs; Weighing the evidence

Expert Opinion on Drug Delivery

Volumn 8, Issue 10, 2011, Pages 1297-1308

  Daley Yates, Peter T ^a   Parkins, David A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bioequivalence; in vitro; Inhaled medicines; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BUDESONIDE; FLUNISOLIDE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; SALMETEROL;

AREA UNDER THE CURVE; ASTHMA; BIOEQUIVALENCE; CLINICAL STUDY; DRUG LEGISLATION; DRUG SCREENING; EVIDENCE BASED PRACTICE; FORCED EXPIRATORY VOLUME; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHALATIONAL DRUG ADMINISTRATION; METERED DOSE INHALER; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; POWDER INHALER; PRACTICE GUIDELINE; REVIEW; VALIDATION PROCESS;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; AEROSOLS; HUMANS; METERED DOSE INHALERS; THERAPEUTIC EQUIVALENCY;

EID: 80053079644     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.592827     Document Type: Review

References (47)

1. The Montreal Protocol. The Montreal protocol on substances that deplete the ozone layer. Final act (Nairobi: UNEP; 1987). Fed Reg 1994;59:56276-98
2. Stewart BA, Ahrens RC, Carrier S, et al. Demonstration of in vivo Bioequivalence of generic albuterol metered dose inhaler to Ventolin. Chest 2000;117(3):714-21 (Pubitemid 30152210)
3. Hindle M, Newton DA. Chrystyn H. investigation of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. Thorax 1993;48:607-10 (Pubitemid 23188433)
4. Hindle M, Chrystyn H. Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation method and spacer devices. Thorax 1994;49:549-53 (Pubitemid 24203157)
5. Hindle LM, Newton DA, Chystyn H. Dry powder in-halers are bioequivalent to metered dose inhalers: a study using a new urinary albuterol (salbutamol) assay technique. Chest 1995;107:629-33
6. Food and Drug Administration. Interim guidance for documentation of In vivo bioequivalence of albuterol aerosols (metered-dose inhalers. Rockville, MD: Division of bioequivalence. Office of generic drugs, food and drug administration; January 27, 1994; Publication No. 1-27
7. Chystyn H. Standard for bioequivalence of inhaled products. Clin Pharmacokinet 1994;26:1-6
8. European Medicines Agency. Committee for Medicinal Products for Human Use. (2007). Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD. Draft. CPMP/EWP/4151/00 Rev 1
9. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. Doc Ref. CPMP/EWP/4151/00 Rev.1. 22 January 2009 Available from: http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/09/WC500003504.pdf [Accessed 30 August 2010]
10. Healthy Canada. Release of Draft Guidance Document: Submission Requirements for Subsequent Market Entry Inhaled Corticosteroid Products for Use in the Treatment of Asthma. 2 August 2007. Available from: http://www.hcsc.gc. ca/dhpmps/alt-formats/hpfbdgpsa/pdf/prodpharma/inhal-corticost-eng.pdf [Accessed 30 August 2010]
11. Adams WP, Ahrens RC, Chen M-L, et al. Demonstrating bioequivalence of locally acting orallyinhaled drug products (OIPs): workshop summary report. J Aerosol Med Pulm Drug Deliv 2010;23:1-29
12. Respiratory Drug Delivery. ILISBN: Book 1, 1-933722-41-X: In: Dalby RN, Byron PR, Peart J, et al. editors. FloridaDavis Healthcare International Publishing; Orlando, River Grove: 2010; vii
13. Respiratory Drug Delivery Online. Available from: http://www. rddonline.com/index.php [Accessed 19 January 2011]
14. International Society for Aerosols in Medicine/International Pharmaceutical Aerosol Consortium on Regulation and Science Workshop in Frankfurt, 12-13 Oct 2010. Available from: http://isam-org.activaero.de/ component/content/article/13/38-ipac [Accessed 19 January 2010]
15. Lee SL, Adams WP, Li BV, et al. In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases. AAPS J 2009;11:414-23
16. Committee for Medicinal Products for Human Use. European medicines agency. 2008). "Guideline on the investigation of bioequivalence, " Draft. CPMP/EWP/QWP/1401/98 Rev 1
17. Product Quality Research Institute workshop on demonstrating bioequivalence of locally acting orally inhaled drug products. Available from: http://www.pqri.org/workshops/imagespdfs/Bioequivalence2009- Final-Agenda.pdf [Accessed 19 January 2011]
18. Dissanayake S. Application of the EU Guidelines for pharmacokinetic studies of locally acting orally inhaled drug products. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM. editors. Respiratory Drug Delivery. ISBN: Book 1, 1-933722-41-X: David Healthcare International Publishing; Orlando Florida, River Grove IL; 2010. p. 293-304
19. Ehtezazi T, Horsfield MA, Barry PW, et al. Dynamic change of the upper airway during inhalation via aerosol delivery devices. J Aerosol Med 2004;17:325-34 (Pubitemid 40116949)
20. Dolovich M, Rhem R. Impact of oropharyngeal deposition on inhaled dose. J Aerosol Med 1998;11:S112-15 (Pubitemid 28286042)
21. Newhouse MT, Dobranowski JA, Chambers C, et al. Development and preliminary validation studies with an ex-vivo oropharyngeal model. In: Byron PR, Dalby RN, Farr SJ, editors. Proceedings of Respiratory Drug Delivery VI. Interpharm Press, Inc., Buffalo Grove, IL.1998, p. 389-91
22. Cheng Y-S, Zhou Y, Chen BT. Particle deposition in a cast of human oral airways. Aerosol Sci Tech 1999;31:286-300 (Pubitemid 32001437)
23. Burnell PKP, Asking L, Borgstrom L, et al. Studies of the human oropharyngeal airspaces using magnetic resonance imaging IV-the oropharyngeal retention effect for four inhalation delivery systems. J Aerosol Med 2007;20:269-81 (Pubitemid 47463183)
24. Olsson B, Berg E, Svennsson M. Comparing aerosol size distributions that penetrate mouth-throat models under realistic inhalation conditions. In: Dalby RN, Byron PR, Peart J, et al. editors. Respiratory Drug Delivery. David Healthcare International Publishing; Orlando Florida, River Grove IL; 2010. p. 225-33
25. Raid AAM, Tarsin WY, Assi KH, et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Resp Med 2007;101:2395-401 (Pubitemid 47471395)
26. Tarsin W, Assi KH, Chrystyn H. In-vitro inhalation flow rate dependent dosage emission and inconsistency from a combination of budesonide and efometrol in a dry powder inhaler. J Aerosol Med 2004;17:25-32 (Pubitemid 38520670)
27. Malton A, Sumby BS, Smith IJ. A comparison of in vitro drug delivery from two multi-dose powder inhalation devices. Eur J Clin Res 1995;7:1-17
28. Prime D. Determining flow and flow acceleration conditions for in-vitro testing of dry powder inhalers. Abstracts from international society of aerosols in medicine, 15th congress; Perth; 2005, p. P68
29. Mitchell J, Newman S, Chan H-K. In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review. AAPS PharmSciTech 2007;8:Article 110
30. Bisgaard H, Klug B, Sumby BS, et al. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 1998;11:1111-15 (Pubitemid 28281031)
31. de Boer AH, Bolhuis GK, Gjaltema D, et al. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers-Part 3: the effect of flow increase rate (FIR) on the in vitro drug release from the Pulmicort 200. Turbuhaler 1997;11:67-77 (Pubitemid 27283335)
32. Finlay WH, Gehmlich MG. Inertial sizing of aerosol inhaled from two dry powder inhalers with realistic breath patterns versus constant flow rates. Int J Pharm 2000;210:83-95 (Pubitemid 32332644)
33. Daley-Yates PT, Parkins DA, Thomas MJ, et al. Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry powder inhalers delivering a combination of salmeterol 50 mug and fluticasone propionate 250mug: implications for establishing bioequivalence of inhaled products. Clin Ther 2009;31:370-85
34. Daley-Yates P. The clinical utility of pharmacokinetics: theoretical consideration across drug classes. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM. editors. Respiratory Drug Delivery. ISBN: Book 1, 1-933722-41-X: David Healthcare International Publishing; Orlando Florida, River Grove IL: 2010. p. 273-84
35. Persson G, Ankerst J, Gillen M, et al. Relative systemic availability of budesonide in patients with asthma after inhalation from two dry powder inhalers. Curr Med Res Opin 2008;24:1511-17 (Pubitemid 351741584)
36. Kerwin EM, Pearlman DS, de Guia T, et al. Evaluation of efficacy, safety, and pharmacokinetics of budesonide delivered via two dry powder inhalers. Curr Med Res Opin 2008;4:1497-510 (Pubitemid 351741583)
37. Lahelma S, Kirjavainen M, Kela M, et al. Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method. Br J Clin Pharmacol 2004;59:167-73 (Pubitemid 40208852)
38. Tukiainen H; on behalf of the Finnish Study Group. Safety, tolerability and acceptability of two dry powder inhalers in the administration of budesonide in steroid-treated asthmatic patients. Respir Med 2002;96:221-9
39. Daley-Yates PT, Bagen S, Tournant J, et al. Beclomethasone dipropionate chlorofluorocarbon and hydrofluoroalkane metered dose inhalers: relationship between systemic exposure, dose, fine particle mass and particle size in healthy volunteers. Eur Resp J 1999;14:1358
40. Falcoz C, Horton J, Mackie AE, et al. Pharmacokinetics of inhaled fluticasone propionate delivered via the Diskhaler and Diskus delivery devices in patients with mild to moderate asthma. Clin Pharmacokinet 2000;39(Suppl 1):31-7
41. Kunka R, Andrews S, Pimazzoni M, et al. Dose proportionality of fluticasone propionate from hydrofluoroalkane inhalers and comparability with chlorofluorocarbon inhalers. Resp Med 2000;94(Suppl B):10-16
42. Clearie KL, Williamson PA, Vaidyanathan S, et al. Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/ salmeterol in healthy volunteers via pMDI alone and spacer. Br J Clin Pharmacol 2010;69:637-44
43. Johnson M. Fluticasone propionate: pharmacokinetic and pharmacodynamic implications of different aerosol delivery systems. In: Byron PR, Dalby RN, Farr SJ. editors. Respiratory Drug Delivery VI. Interpharm Press, Inc; Buffalo Grove, IL: 1998. p. 61-70
44. Mackie AE, McDowall JE, Falcoz C, et al. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy subjects. Clin Pharmacokinet 2000;39(Suppl 1):23-30
45. Noltinga A, Sistab S, Abramowitza W. Flunisolide HFA vs Flunisolide CFC:. Pharmacokinetic comparison in healthy volunteers. Biopharm Drug Dispos 2001;22:373-82
46. Lawrence M, Wolfe J, Webb DR, et al. Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity. Am J Respir Crit Care Med 1997;156:744-51 (Pubitemid 27396410)
47. O'Connor D, Adams WP, Chen M-L, et al. Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report. J Aerosol Med Pulm Drug Deliv 2011;24:1-17